Press Releases
NanoString Launches First Simple and Precise Approach to Detect Hundreds of Genetic Copy Variants in a Single Multiplexed Reaction
NanoString Technologies, Inc., a privately held life sciences company marketing a complete solution for detecting and counting large sets of target molecules in biological samples, announced the launch of a novel solution for detecting genetic copy number variations (CNVs)...
Press Releases
Merrion Pharmaceuticals Plc announces commencement of feasibility and option agreement with Rebel Pharmaceuticals
Merrion Pharmaceuticals Plc, a publicly listed product development company, announced the commencement of an oral drug delivery feasibility and option agreement with Rebel Pharmaceuticals, LLC, on two undisclosed compounds. The agreement will evaluate the ability of Merrion's patented GIPET®...
Press Releases
Abbott Announces Positive Results from Phase 2 Study of Low Dose Atrasentan for Treatment of Diabetic Kidney Disease
Abbott announced positive results from a Phase 2 dose-ranging study of atrasentan, a highly selective endothelin A receptor (ETAR) antagonist in development to help slow chronic kidney disease (CKD) progression in patients with type 2 diabetic nephropathy (diabetic kidney...
Press Releases
Reata and Abbott Announce Positive Phase 2b Study Results for Bardoxolone Methyl
Reata Pharmaceuticals and Abbott announced data from a Phase 2b study which suggests that bardoxolone methyl, an investigational treatment for chronic kidney disease (CKD), may reduce the stage of CKD and improve estimated glomerular filtration rate (eGFR) and other...
Press Releases
Pfizer Launches Global Centers for Therapeutic Innovation, a Network of Research Partnerships
Pfizer Inc. announced the establishment of the Global Centers for Therapeutic Innovation, an entrepreneurial network of partnerships with leading academic medical centers to transform research and development by accessing leading translational researchers. Â The University of...
Press Releases
Novartis unveils long-term strategy to grow in a dynamically changing healthcare environment
Novartis presented today a strategic overview of the company's diversified healthcare portfolio which creates the potential for future sustainable growth. The company's focused healthcare portfolio across key growth segments in healthcare provides Novartis a leading position in the respective...
Press Releases
Pfizer Inc, Study Shows Adding INSPRA to Standard Therapy Significantly Reduces the Risk of CV Mortality and Morbidity in Patients With Chronic Heart Failure
Pfizer Inc. announced results from the EMPHASIS-HF trial(1) showing a statistically significant reduction in risk of cardiovascular (CV) death or heart failure (HF) hospitalization for patients with chronic heart failure with mild symptoms treated with Inspra® (eplerenone) versus those...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read